Ramon, CA (DCS Innovative Diagnostik-Systeme GmbH, Hamburg, Germany)]. Thereafter, sections were rinsed twice in PBS, incubated with fast red substrate (Fast Red Substrate System, DakoCytomation GmbH) and counterstained with haematoxylin (DakoCytomation GmbH). Statistical Analysis All results were expressed as the mean standard deviation (SD) and repeated at least three times as indicated in the figures. References 1. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, et al. (2007) Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. Aids 21: 1073–1089. 2. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ (1994) Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 84: 1020–1023. 3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33: 562–569. 4. Rockstroh JK, Spengler U (2004) HIV and hepatitis C virus co-infection. Lancet Infect Dis 4: 437–444. 5. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, et al. (2001) Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34: 283–287. 6. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, et al. (2004) Incidence and predictors of severe liver fibrosis in human immunode- ficiency virus-infected patients with chronic hepatitis C: a European collabora- tive study. Clin Infect Dis 38: 128–133. 7. Woitas RP, Rockstroh JK, Beier I, Jung G, Kochan B, et al. (1999) Antigen- specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. Aids 13: 1313–1322. 8. Laskus T, Radkowski M, Jablonska J, Kibler K, Wilkinson J, et al. (2004) Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood 103: 3854–3859. 9. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS (1996) Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 41: 1265–1272. 10. Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE (2003) Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 188: 1192–1204. 11. Guicciardi ME, Gores GJ (2010) Apoptosis as a mechanism for liver disease progression. Semin Liver Dis 30: 402–410. 12. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ (2004) Bile acids up- regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 279: 51–60. 13. Walter D, Schmich K, Vogel S, Pick R, Kaufmann T, et al. (2008) Switch from type II to I Fas/CD95 death signaling on in vitro culturing of primary hepatocytes. Hepatology 48: 1942–1953. 14. Babu CK, Suwansrinon K, Bren GD, Badley AD, Rizza SA (2009) HIV induces TRAIL sensitivity in hepatocytes. PLoS ONE 4: e4623. 15. Balasubramanian A, Koziel M, Groopman JE, Ganju RK (2005) Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV. Clin Infect Dis 41 Suppl 1: S32–37. 16. Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628–8633. 17. Macias J, Japon MA, Saez C, Palacios RB, Mira JA, et al. (2005) Increased Hepatocyte Fas Expression and Apoptosis in HIV and Hepatitis C Virus Coinfection. J Infect Dis 192: 1566–1576. 18. Bantel H, Ruck P, Schulze-Osthoff K (2000) In situ monitoring of caspase activation in hepatobiliary diseases. Cell Death Differ 7: 504–505. 19. Bantel H, Schulze-Osthoff K (2003) Apoptosis in hepatitis C virus infection. Cell Death Differ 10 Suppl 1: S48–58. 20. Ammanamanchi S, Freeman JW, Brattain MG (2003) Acetylated sp3 is a transcriptional activator. J Biol Chem 278: 35775–35780. 21. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, et al. (2003) Involvement of TRAIL and its receptors in viral hepatitis. Faseb J 17: 94–96. 22. Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, et al. (2005) Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54: 1590–1596. 23. Jang JY, Shao RX, Lin W, Weinberg E, Chung WJ, et al. (2011) HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol 54: 612–620. 24. Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV (2003) Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 188: 1455–1460. HCV Hepatocytes Kill HIV Hepatocytes through TRAIL Statistical comparisons were made by student’s t test employed to calculate the significance between the paired observations. A P value of 0.05 was used as the level of significance. Author Contributions Conceived and designed the experiments: SAR ADB. Performed the experiments: SN KBC JS HW GDB. Analyzed the data: SAR ADB. Wrote the paper: SAR ADB. 25. Fischer R, Baumert T, Blum HE (2007) Hepatitis C virus infection and apoptosis. World J Gastroenterol 13: 4865–4872. 26. Berg CP, Schlosser SF, Neukirchen DK, Papadakis C, Gregor M, et al. (2009) Hepatitis C virus core protein induces apoptosis-like caspase independent cell death. Virol J 6: 213. 27. Chou AH, Tsai HF, Wu YY, Hu CY, Hwang LH, et al. (2005) Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 174: 2160–2166. 28. Mohd-Ismail NK, Deng L, Sukumaran SK, Yu VC, Hotta H, et al. (2009) The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human Mcl-1. J Virol 83: 9993–10006. 29. Saito K, Meyer K, Warner R, Basu A, Ray RB, et al. (2006) Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 80: 4372–4379. 30. Bird GL, Spence E, Hillan KJ, MacSween RN, Frame D, et al. (1995) Genotypic variation, clinical and histological characteristics of chronic hepatitis C detected at blood donor screening. J Viral Hepat 2: 261–265. 31. Winslow DL (2006) Hepatocyte apoptosis in hepatitis C/HIV co-infection. AIDS Alert 21: 142–143. 32. Cao Y, Qin L, Zhang L, Safrit J, Ho DD (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332: 201–208. 33. Lefkowitch JH (1994) Pathology of AIDS-related liver disease. Dig Dis 12: 321–330. 34. Cummins NW, Badley AD (2011) Mechanisms of HIV-associated lymphocyte apoptosis. Cell Death and Disease 1. 35. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA (2005) HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12 Suppl 1: 878–892. 36. Hesselgesser J, Taub D, Baskar P, Greenberg M, Hoxie J, et al. (1998) Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol 8: 595–598. 37. Liang X, Du J, Liu Y, Cui M, Ma C, et al. (2007) The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis 12: 1827–1836. 38. Liang X, Liu Y, Zhang Q, Gao L, Han L, et al. (2007) Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol 178: 503–510. 39. Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ (2007) Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 56: 1124–1131. 40. Guo L, Fan L, Ren J, Pang Z, Ren Y, et al. (2011) A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor- targeting of liposomes. Nanotechnology 22: 265105. 41. Schneider-Jakob S, Corazza N, Badmann A, Sidler D, Stuber-Roos R, et al. (2010) Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid. Cell Death Dis 1: e86. 42. Tian X, Ye J, Alonso-Basanta M, Hahn SM, Koumenis C, et al. (2011) Modulation of CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)-dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL). J Biol Chem 286: 29408–29416. 43. Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, et al. (2010) Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138: 1885–1897. 44. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, et al. (2007) Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133: 1649–1659. 45. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, et al. (2011) Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combina- tion Therapy. Intervirology. 46. Cummins NW, Rizza SA, Badley AD (2010) How much gp120 is there? J Infect Dis 201: 1273-1274; author reply 1274-1275. PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27171